Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background A dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG+DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with resistance or intolerance to nucleoside reverse transcriptase inhibitors, especially those with a history of treatment failure. Materials and Methods We included all treatment-experienced patients with HIV who switched to the DTG+DRV/c regimen at a tertiary university hospital. We assessed the regimen's effectiveness, safety, and tolerability through serial laboratory data and clinical findings. The primary endpoint was the proportion of patients with plasma HIV-RNA levels <50 copies/mL at week 144 post-switch. The secondary endpoints were safety and tolerability assessments. Results Our retrospective analysis involved 40 patients. The leading reasons for switching to DTG+DRV/c were treatment failure in 17 patients (42.5%), simplification after multiple previous regimens in 15 (37.5%), and adverse drug reactions in 8 (20.0%). Among the 17 patients in the treatment failure group, we observed enhanced viral suppression and improved CD4+ T-cell counts after initiating the dual regimen. In the non-treatment failure group (23 patients), viral suppression and CD4+ T-cell levels were consistently maintained. No significant alterations in renal function, liver function, glucose levels, or lipid profiles were observed post-switch. High tolerability was observed, with 34/40 patients (85.0%) responding well to the regimen. However, six patients discontinued treatment before reaching the 144-week mark. Conclusion Our findings confirm that DTG+DRV/c is an effective and well-tolerated switch therapy regimen for treatment-experienced patients with HIV, with sustained benefits observed for up to 144 weeks of follow-up. This regimen showed adaptability across different patient groups and demonstrated virological and immunological improvements, particularly in patients with a history of treatment failure.
Abstract
Background A dual regimen with dolutegravir plus cobicistat-boosted darunavir (DTG+DRV/c) is a promising alternative for patients with human immunodeficiency virus (HIV) with resistance or intolerance to nucleoside reverse transcriptase inhibitors, especially those with a history of treatment failure. Materials and Methods We included all treatment-experienced patients with HIV who switched to the DTG+DRV/c regimen at a tertiary university hospital. We assessed the regimen's effectiveness, safety, and tolerability through serial laboratory data and clinical findings. The primary endpoint was the proportion of patients with plasma HIV-RNA levels <50 copies/mL at week 144 post-switch. The secondary endpoints were safety and tolerability assessments. Results Our retrospective analysis involved 40 patients. The leading reasons for switching to DTG+DRV/c were treatment failure in 17 patients (42.5%), simplification after multiple previous regimens in 15 (37.5%), and adverse drug reactions in 8 (20.0%). Among the 17 patients in the treatment failure group, we observed enhanced viral suppression and improved CD4+ T-cell counts after initiating the dual regimen. In the non-treatment failure group (23 patients), viral suppression and CD4+ T-cell levels were consistently maintained. No significant alterations in renal function, liver function, glucose levels, or lipid profiles were observed post-switch. High tolerability was observed, with 34/40 patients (85.0%) responding well to the regimen. However, six patients discontinued treatment before reaching the 144-week mark. Conclusion Our findings confirm that DTG+DRV/c is an effective and well-tolerated switch therapy regimen for treatment-experienced patients with HIV, with sustained benefits observed for up to 144 weeks of follow-up. This regimen showed adaptability across different patient groups and demonstrated virological and immunological improvements, particularly in patients with a history of treatment failure.
참고문헌 (24)
- "Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV"[URL]
- "HIV drug resistance report 2021"[URL]
- Boucher CA, "State of the art in HIV drug resistance : science and technology knowledge gap", AIDS Rev, 20, pp.27~42 (2018)
- Pennings PS, "HIV drug resistance : problems and perspectives", Infect Dis Rep, 5(Suppl 1), pp.e5~ (2013)
- Orkin C, "Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment : assessing the evidence", HIV Med, 19, pp.18~32 (2018)
- Wolf E, "Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance", AIDS Res Ther, 18, pp.58~ (2021)
- Soriano V, "A new HIV paradigm : dual antiretroviral regimens as maintenance therapy", AIDS Rev, 19, pp.113~114 (2017)
- Spinner CD, "Pharmacokinetics of once-daily dolutegravir and ritonavir-boosted darunavir in HIV patients : the DUALIS study", J Antimicrob Chemother, 72, pp.2679~2681 (2017)
- Santos JR, "A randomized trial of dolutegravir plus darunavir", cobicistat as a switch strategy in HIV-1-infected patients with resistance to at least 2 antiretroviral classes, 2023, pp.10, ofad542~
- Capetti AF, "A dual regimen of ritonavir", darunavir plus dolutegravir for rescue or simplification of rescue therapy : 48 weeks' observational data, 2017, pp.17, 658~
- Hawkins KL, "Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals", Antivir Ther, 24, pp.513~519 (2019)
- Lee SA, "Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus", Infect Chemother, 50, pp.252~262 (2018)
- Laprise C, "Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients : results from 12 years of observation", Clin Infect Dis, 57, pp.1489~1496 (2013)
- Orkin C, "Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection : week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials", Lancet HIV, 7, pp.e389~e400 (2020)
- Palmier E, "Three-year efficacy of switching to dolutegravir plus lamivudine : a real-world study", HIV Med, 24, pp.1013~1019 (2023)
- Kandel CE, "Dolutegravir-a review of the pharmacology, efficacy, and safety in the treatment of HIV", Drug Des Devel Ther, 9, pp.3547~3555 (2015)
- Ombajo LA, "Second-line switch to dolutegravir for treatment of HIV infection", N Engl J Med, 388, pp.2349~2359 (2023)
- Zakumumpa H, "Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda : a qualitative study", BMC Infect Dis, 21, pp.1222~ (2021)
- Navarro J, "Effectiveness of once", day dolutegravir plus boosted darunavir as a switch strategy in heavily treated patients with human immunodeficiency virus, 2019, pp.39, 501~507
- Vizcarra P, "Efficacy and safety of dolutegravir plus boosted-darunavir dual therapy among highly treatment-experienced patients", Antivir Ther, 24, pp.467~471 (2019)
- Jabłonowska E, "Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients", PLoS One, 14, pp.e0210476~ (2019)
- Iacob SA, "Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations", Front Pharmacol, 8, pp.831~ (2017)
- Li M, "Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants", Sci Adv, 9, pp.eadg5953~ (2023)
- Butler K, "Cost-effectiveness and budget impact of dolutegravir", lamivudine for treatment of human immunodeficiency virus(HIV-1)infection in the United States, 2021, pp.27, 891~903